InBios International, Inc products

Smart Detect^TM SARS-CoV-2 rRT-PCR Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in human nasopharyngeal swab, anterior nasal swab and mid-turbinate nasal swab specimens from individuals suspected of COVID-19 by their healthcare provider. Clinical laboratories that are certified under Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, to perform high complexity tests in the U.S. can immediately begin using this kit, which offers results in about 4 hours.

The SCoV-2 Ag Detect™ Rapid Self-Test’s patent pending design has been developed to be incredibly simple to use. It uses a shallow nasal swab (inserted just one-half inch) and offers easy-to-read results – all in the time it takes to drink your morning latte, go for a mile run or read a couple of chapters in your latest novel.

The SCoV-2 Detect™ IgG Rapid Test is an in vitro lateral flow chromatographic immunoassay intended for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum, plasma (sodium citrate, dipotassium EDTA and sodium heparin), venous whole blood (sodium citrate, dipotassium EDTA and sodium heparin), and fingerstick whole blood.  The SCoV-2 Detect™ IgG Rapid Test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The SCoV-2 Detect™ IgG Rapid Test should not be used to diagnose or exclude acute SARS-CoV-2 infection. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity.

The Chagas Detect^TM Plus (CDP) Rapid Test is a rapid immunochromatographic strip assay for the qualitative detection of human lgG antibodies to Trypanosoma cruzi (T. cruzi) in human serum and whole blood matrices (venous and capillary (finger prick) whole blood). CDP is a non-invasive diagnostic test for use in a primary care setting by personnel trained to obtain whole blood or serum samples. Reactive test results will be presumptive evidence of infection with T. cruzi. The CDP when used in conjunction with other serological and clinical information is useful for the diagnosis of individuals with Chagas disease. Definitive diagnosis of an acute phase infection (including acute congenital infection) must be made by alternative methods, e.g., hemoculture, blood smear. This test is not intended for use on cord blood or for screening blood or plasma donors.